On June 18, 2025, Aptevo Therapeutics Inc. entered into a securities purchase agreement to sell approximately 2.1 million shares of its common stock and warrants to institutional investors, raising about $7.45 million for development and working capital. The closing occurred on June 20, 2025, with each common stock share priced at $3.25.